

Accepted Manuscript

Design and synthesis of aryloxypropanolamine as β_3 -adrenergic receptor antagonist in cancer and lipolysis

Jiyu Jin, Chunxiao Miao, Zhilong Wang, Wanli Zhang, Xiongwen Zhang, Xin Xie, Wei Lu

PII: S0223-5234(18)30275-7

DOI: [10.1016/j.ejmech.2018.03.032](https://doi.org/10.1016/j.ejmech.2018.03.032)

Reference: EJMECH 10297

To appear in: *European Journal of Medicinal Chemistry*

Received Date: 15 November 2017


Revised Date: 5 March 2018

Accepted Date: 9 March 2018

Please cite this article as: J. Jin, C. Miao, Z. Wang, W. Zhang, X. Zhang, X. Xie, W. Lu, Design and synthesis of aryloxypropanolamine as β_3 -adrenergic receptor antagonist in cancer and lipolysis, *European Journal of Medicinal Chemistry* (2018), doi: 10.1016/j.ejmech.2018.03.032.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.





In vitro, compound **23d** was found to display 23-fold more potent Beta3-AR antagonist activity ($EC_{50} = 0.5117$ nM) than L-748,337 ($EC_{50} = 11.91$ nM).

In vivo, compound **23d** could alleviate weight loss and inhibit tumor growth in C26 tumor cachexia animal model.

Download English Version:

<https://daneshyari.com/en/article/7796623>

Download Persian Version:

<https://daneshyari.com/article/7796623>

[Daneshyari.com](https://daneshyari.com)